Citations 2
Highlights From the Annual Meeting of the American Epilepsy Society 2022
Valencia, Ignacio , Alexander, Allyson , Andrade, Danielle M. , Arévalo, Miguel , Auer, Nancy A. , Bartoloméi, Fabrice , Becker, Danielle A. , Bernasconi, Andrea , Bernasconi, Neda , Bhatnagar, Shivani , Blumenfeld, Hal , Burdette, David E. , Conner, Kelly , Conway, Jeannine M. , Diaz-Arastia, Ramon, Drees, Cornelia , French, Jacqueline A. , Ganguly, Taneeta M. , Gotman, Jean , Guilfoyle, Shanna M., Gupta, Gita , Hentges, Katie, Huh, Linda , Kelley, Sarah A. , Vega‐Talbott, Maite La, Lam, Alice , Lowenstein, Daniel H. , Maturu, Sarita , McDonald, Carrie R. , McKee, Heather , Meador, Kimford J. , Michael, Elizabeth H., Mikati, Mohamad A. , Mitchell, James , Myers, Leah S. , Naritoku, Dean K., Neville, Kerri, Pavlova, Milena , Perry, Μ. Scott , Plueger, Madona, Pugh, Mary Jo , Quigg, Mark , Reddy, Shilpa B. , Reynolds, Tamara S. , Santana‐Gomez, Cesar , Schommer, Linsday, Shellhaas, Renée A. , Shrey, Daniel W. , Singh, Rani K. , Suleman, Saher, Templer, Jessica W. , Varadkar, Sophia , Velez‐Ruiz, Naymee , Velı́šková, Jana , Voskobiynyk, Yuliya , Wagner, Janelle L. , Wagnon, Jacy L. , Waller, Claire, Waller, Jill, Welborn, Michelle, Shellhaas, Renée A , Mikati, Mohamad A , Andrade, Danielle M , French, Jacqueline , Meador, Kimford J , Templer, Jessica W , McKee, Heather Ravvin , Ganguly, Taneeta Mindy , Burdette, David E , Valencia, Ignacio , Arevalo-Astrada, Miguel, Rubiños, Clio , Auer, Nancy, Bainbridge, Jacquelyn L. , Baxendale, Sallie , Berg, Anne T. , Bernhardt, Boris C. , Bhatnagar, Shivani, Blümcke, Ingmar , Buchanan, Gordon F. , Burneo, Jorge G. , Busch, Robyn M. , Chauvel, Patrick , Chin, Jeannie , Clifford, Lisa M. , Cook, Mark , Drees, Cornelia , Gelfand, Michael , Glauser, Tracy A. , Gleichgerrcht, Ezequiel L. , Goldman, Alica M. , González-Martínez, Jorge , Grinspan, Zachary M. , Hammer, Michael F. , Hartman, Adam L. , Hogan, R Edward , Hyslop, Ann , Jobst, Barbara C. , Josephson, Colin B. , Knupp, Kelly G. , Koepp, Matthias J. , Kothare, Sanjeev V. , Krook-Magnuson, Esther , Kwasa, Jasmine A. C. , Lee, Jong Woo , Mayor, Luis Carlos , McKhann, Guy M. , Mefford, Heather C. , Millichap, J Gordon , Noebels, Jeffrey L. , O’Brien, Terence J. , Oluigbo, Chima , Patel, Anup D. , Paz, Jeanne T. , Pennell, Page B. , Perucca, Piero , Pitkänen, Asla , Ryan, Christopher, Sajatovic, Martha , Schuele, Stephan , Sperling, Michael R. , Thom, Maria , Trinka, Eugen , Wang, Irène , Wirrell, Elaine
Epilepsy Currents | August 17, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available
With more than 6000 attendees between in-person and virtual offerings, the American Epilepsy Society Meeting 2022 in Nashville, felt as busy as in prepandemic times. An ever-growing number of physicians, scientists, and allied health professionals gathered to learn a variety of topics about epilepsy. The program was carefully tailored to meet the needs of professionals with different interests and career stages. This article summarizes the different symposia presented at the meeting. Basic science lectures addressed the primary elements of seizure generation and pathophysiology of epilepsy in different disease states. Scientists congregated to learn about anti-seizure medications, mechanisms of action, and new tools to treat epilepsy including surgery and neurostimulation. Some symposia were also dedicated to discuss epilepsy comorbidities and practical issues regarding epilepsy care. An increasing number of patient advocates discussing their stories were intertwined within scientific activities. Many smaller group sessions targeted more specific topics to encourage member participation, including Special Interest Groups, Investigator, and Skills Workshops. Special lectures included the renown Hoyer and Lombroso, an ILAE/IBE joint session, a spotlight on the impact of Dobbs v. Jackson on reproductive health in epilepsy, and a joint session with the NAEC on coding and reimbursement policies. The hot topics symposium was focused on traumatic brain injury and post-traumatic epilepsy. A balanced collaboration with the industry allowed presentations of the latest pharmaceutical and engineering advances in satellite symposia.
New Antiepileptic Drugs: Focus on Ezogabine, Clobazam, and Perampanel
Rudzinski, Leslie A., Velez‐Ruiz, Naymee , Gedzelman, Evan , Mauricio, Elizabeth A. , Shih, Jerry J. , Karakis, Ioannis , Mauricio, Elizabeth A. , Karakis, Ioannis
Journal of Investigative Medicine | June 2, 2016 | Volume: 64 | Issue: 6 | Pages: 1087-1101
Ezogabine, clobazam, and perampanel are among the newest antiseizure drugs approved by the Food and Drug Administration between 2011 and 2012. Ezogabine and perampanel are approved for adjunctive treatment of partial epilepsy. Perampanel is also approved for adjunctive treatment of primary generalized tonic–clonic seizures. Ezogabine and perampanel have novel mechanisms of action. Ezogabine binds to voltage-gated potassium channels and increases the M-current thereby causing membrane hyperpolarization. Perampanel is a selective, non-competitive 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid receptor antagonist, which reduces neuronal excitation. Clobazam has been used worldwide since the 1970s and is approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. Clobazam is the only 1,5-benzodiazepine currently in clinical use, which is less sedating than the commonly used 1,4-benzodiazepines. Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated efficacy and good tolerability of these 3 new antiepileptic drugs. These drugs represent a welcome addition to the armamentarium of practitioners, but it remains to be seen how they will affect the landscape of pharmacoresistant epilepsy.